Liège, Belgium – 08 February 2024, 07:00 AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will release its full year 2023 fiscal results on Thursday, 14 March 2024, at 07.00 AM CET.
Following the release, the company will host a live webcast to discuss 2023 results and the outlook for 2024. Participants will have a chance to interact with Stijn Van Rompay, CEO and Jean-Luc Vandebroek, CFO in a question-and-answer session. The details of the event are below:
Date: Thursday, 14 March
Time: 02.00pm CET
Registration: Hyloris Annual Results 2023 Webcast
About Hyloris Pharmaceuticals SA
Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors.
The Company’s development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA’s 505(b)2 pathway in the …
Leave a Reply